Agenus Inc. vs. Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 5 of 9 compared factors.
Size & Scale
| AGEN | HALO | |
|---|---|---|
| Market Cap | $334.50 million | $12.29 billion |
| Revenue (TTM) | $132.69 million | $1.66 billion |
| Net Income (TTM) | $91.94 million | $413.60 million |
HALO leads on 3 of 3 size & scale factors.
Valuation
| AGEN | HALO | |
|---|---|---|
| P/E Ratio | 2.88 | 31.67 |
| Price / Book | -1.62 | 85.64 |
| Price / Sales | 2.52 | 7.39 |
AGEN leads on 3 of 3 valuation factors.
Profitability
| AGEN | HALO | |
|---|---|---|
| Net Margin | 69.29% | 24.86% |
| Return on Equity | -44.66% | 288.13% |
AGEN and HALO split the profitability factors evenly.
Risk & Sentiment
| AGEN | HALO | |
|---|---|---|
| Short Interest | 22.67% | 9.79% |
HALO leads on 1 of 1 risk & sentiment factors.
Dig deeper: AGEN overview, AGEN financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.